CN107912042A - 用于治疗疾病的稠合双环化合物 - Google Patents

用于治疗疾病的稠合双环化合物 Download PDF

Info

Publication number
CN107912042A
CN107912042A CN201680029952.3A CN201680029952A CN107912042A CN 107912042 A CN107912042 A CN 107912042A CN 201680029952 A CN201680029952 A CN 201680029952A CN 107912042 A CN107912042 A CN 107912042A
Authority
CN
China
Prior art keywords
optionally substituted
alkyl
formula
hydrogen
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680029952.3A
Other languages
English (en)
Chinese (zh)
Inventor
R·莫汉
B·A·普拉特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Akarna Therapeutics Ltd
Original Assignee
Akarna Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akarna Therapeutics Ltd filed Critical Akarna Therapeutics Ltd
Publication of CN107912042A publication Critical patent/CN107912042A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN201680029952.3A 2015-03-26 2016-03-25 用于治疗疾病的稠合双环化合物 Pending CN107912042A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562138725P 2015-03-26 2015-03-26
US62/138,725 2015-03-26
PCT/IB2016/000606 WO2016151403A1 (en) 2015-03-26 2016-03-25 Fused bicyclic compounds for the treatment of disease

Publications (1)

Publication Number Publication Date
CN107912042A true CN107912042A (zh) 2018-04-13

Family

ID=56072361

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680029952.3A Pending CN107912042A (zh) 2015-03-26 2016-03-25 用于治疗疾病的稠合双环化合物

Country Status (16)

Country Link
US (4) US10421759B2 (cg-RX-API-DMAC10.html)
EP (2) EP3715348A1 (cg-RX-API-DMAC10.html)
JP (1) JP6843061B2 (cg-RX-API-DMAC10.html)
KR (1) KR20180003545A (cg-RX-API-DMAC10.html)
CN (1) CN107912042A (cg-RX-API-DMAC10.html)
AU (2) AU2016238523A1 (cg-RX-API-DMAC10.html)
BR (1) BR112017020374A2 (cg-RX-API-DMAC10.html)
CA (1) CA2980394A1 (cg-RX-API-DMAC10.html)
CL (1) CL2017002405A1 (cg-RX-API-DMAC10.html)
CO (1) CO2017010621A2 (cg-RX-API-DMAC10.html)
HK (1) HK1249756A1 (cg-RX-API-DMAC10.html)
IL (1) IL254572A0 (cg-RX-API-DMAC10.html)
MX (1) MX370897B (cg-RX-API-DMAC10.html)
RU (2) RU2021107054A (cg-RX-API-DMAC10.html)
SG (2) SG10201908881PA (cg-RX-API-DMAC10.html)
WO (1) WO2016151403A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2021107054A (ru) * 2015-03-26 2021-03-31 Акарна Терапьютикс, Лтд. Конденсированные бициклические соединения для лечения заболевания
JP2019520335A (ja) * 2016-05-25 2019-07-18 アカーナ・セラピューティクス・リミテッドＡｋａｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｌｔｄ． 疾患治療用の縮合二環式化合物
MX2018014024A (es) * 2016-05-25 2019-08-29 Akarna Therapeutics Ltd Terapias de combinación con moduladores del receptor x farnesoide (fxr).
BR112019025228A2 (pt) * 2017-06-02 2020-06-23 Akarna Therapeutics, Ltd. Compostos bicíclicos fundidos
CN108264474B (zh) * 2018-02-09 2019-10-25 浙江师范大学 一种色胺及其衍生物的合成方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003099821A1 (en) * 2002-05-24 2003-12-04 X-Ceptor Therapeutics, Inc. Azepinoindole and pyridoindole derivatives as pharmaceutical agents
WO2005009387A2 (en) * 2003-07-23 2005-02-03 X-Ceptor Therapeutics Inc. Azepine derivatives as pharmaceutical agents
US20090131409A1 (en) * 2007-10-22 2009-05-21 Wyeth 1,4,5,6,7,8-HEXAHYDRO -PYRROLO[2,3-d]AZEPINES AND -IMIDAZO[4,5-d]AZEPINES AS MODULATORS OF NUCLEAR RECEPTOR ACTIVITY
US20090203577A1 (en) * 2005-12-15 2009-08-13 Exelixis, Inc. Azepinoindole Derivatives As Pharmaceutical Agents
WO2010036362A1 (en) * 2008-09-26 2010-04-01 Wyeth 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595311B2 (en) * 2002-05-24 2009-09-29 Exelixis, Inc. Azepinoindole derivatives as pharmaceutical agents
EP1776112A4 (en) 2004-08-10 2009-11-25 Exelixis Inc HETEROCYCLIC COMPOUNDS AS PHARMACEUTICAL AGENTS
WO2006109633A1 (ja) 2005-04-07 2006-10-19 Daiichi Sankyo Company, Limited 置換インドール化合物
EP2121621B1 (en) 2006-12-08 2014-05-07 Exelixis Patent Company LLC Lxr and fxr modulators
US20090137554A1 (en) 2007-10-22 2009-05-28 Wyeth 1,4,5,6-TETRAHYDRO -PYRROLO[2,3-d]AZEPINES AND -IMIDAZO[4,5-d]AZEPINES AS MODULATORS OF NUCLEAR RECEPTOR ACTIVITY
CA2968434A1 (en) * 2014-11-21 2016-05-26 Akarna Therapeutics, Ltd. Fused bicyclic compounds for the treatment of disease
RU2741387C2 (ru) * 2014-12-22 2021-01-25 Акарна Терапьютикс, Лтд. Конденсированные бициклические соединения для лечения заболевания
RU2021107054A (ru) * 2015-03-26 2021-03-31 Акарна Терапьютикс, Лтд. Конденсированные бициклические соединения для лечения заболевания

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003099821A1 (en) * 2002-05-24 2003-12-04 X-Ceptor Therapeutics, Inc. Azepinoindole and pyridoindole derivatives as pharmaceutical agents
WO2005009387A2 (en) * 2003-07-23 2005-02-03 X-Ceptor Therapeutics Inc. Azepine derivatives as pharmaceutical agents
US20090203577A1 (en) * 2005-12-15 2009-08-13 Exelixis, Inc. Azepinoindole Derivatives As Pharmaceutical Agents
US20090131409A1 (en) * 2007-10-22 2009-05-21 Wyeth 1,4,5,6,7,8-HEXAHYDRO -PYRROLO[2,3-d]AZEPINES AND -IMIDAZO[4,5-d]AZEPINES AS MODULATORS OF NUCLEAR RECEPTOR ACTIVITY
WO2010036362A1 (en) * 2008-09-26 2010-04-01 Wyeth 1,2,3,6-tetrahydroazepino[4,5-b]indole-5-carboxylate nuclear receptor inhibitors

Also Published As

Publication number Publication date
WO2016151403A1 (en) 2016-09-29
MX370897B (es) 2020-01-09
JP2018510876A (ja) 2018-04-19
US20180118752A1 (en) 2018-05-03
EP3274350A1 (en) 2018-01-31
CL2017002405A1 (es) 2018-04-27
HK1249756A1 (zh) 2018-11-09
CA2980394A1 (en) 2016-09-29
SG11201707610PA (en) 2017-10-30
US10421759B2 (en) 2019-09-24
IL254572A0 (en) 2017-11-30
AU2020256301A1 (en) 2020-11-05
US20230002394A1 (en) 2023-01-05
CO2017010621A2 (es) 2018-01-31
RU2017137366A3 (cg-RX-API-DMAC10.html) 2019-07-17
RU2021107054A (ru) 2021-03-31
EP3715348A1 (en) 2020-09-30
MX2017012342A (es) 2018-06-11
RU2017137366A (ru) 2019-04-26
US20210214362A1 (en) 2021-07-15
JP6843061B2 (ja) 2021-03-17
SG10201908881PA (en) 2019-11-28
AU2016238523A1 (en) 2017-11-09
BR112017020374A2 (pt) 2018-06-05
KR20180003545A (ko) 2018-01-09
US20200079782A1 (en) 2020-03-12

Similar Documents

Publication Publication Date Title
JP7224102B2 (ja) 疾患治療用の縮合二環式化合物
JP7089566B2 (ja) 疾患の処置のための縮合二環式化合物
US20210214362A1 (en) Fused bicyclic compounds for the treatment of disease
HK40049146A (en) Fused bicyclic compounds for the treatment of disease
HK1245795B (en) Fused bicyclic compounds for the treatment of disease
BR112017010627B1 (pt) Composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica e respectivos usos
HK1244802B (en) Fused bicyclic compounds for the treatment of disease

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Buckinghamshire

Applicant after: Study of limited acana treatment

Address before: London, England

Applicant before: Study of limited acana treatment

CB02 Change of applicant information
RJ01 Rejection of invention patent application after publication

Application publication date: 20180413

RJ01 Rejection of invention patent application after publication